Hubei Jumpcan Pharmaceutical
Market Cap
CN¥17.7b
Last Updated
2021/04/11 09:02 UTC
Data Sources
Company Financials +
Executive Summary
Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemical based Chinese traditional medicines, and Chinese medicine health products in China. More Details
Rewards
Risk Analysis
Snowflake Analysis
Very undervalued with excellent balance sheet.
Share Price & News
How has Hubei Jumpcan Pharmaceutical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 600566 is less volatile than 75% of CN stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 600566's weekly volatility (3%) has been stable over the past year.
Market Performance
7 Day Return
-1.3%
600566
-0.1%
CN Pharmaceuticals
-1.1%
CN Market
1 Year Return
-8.4%
600566
15.8%
CN Pharmaceuticals
28.4%
CN Market
Return vs Industry: 600566 underperformed the CN Pharmaceuticals industry which returned 14.4% over the past year.
Return vs Market: 600566 underperformed the CN Market which returned 27.4% over the past year.
Shareholder returns
| 600566 | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.3% | -0.1% | -1.1% |
| 30 Day | -1.4% | 3.9% | 1.0% |
| 90 Day | -1.2% | -5.4% | -5.8% |
| 1 Year | -3.2%-8.4% | 16.9%15.8% | 30.4%28.4% |
| 3 Year | -54.0%-58.8% | 25.2%20.7% | 25.9%19.9% |
| 5 Year | -6.0%-20.0% | 41.6%34.1% | 23.6%15.5% |
Long-Term Price Volatility Vs. Market
How volatile is Hubei Jumpcan Pharmaceutical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Hubei Jumpcan Pharmaceutical undervalued compared to its fair value and its price relative to the market?
23.5%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 600566 (CN¥19.94) is trading below our estimate of fair value (CN¥26.07)
Significantly Below Fair Value: 600566 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 600566 is good value based on its PE Ratio (12.7x) compared to the CN Pharmaceuticals industry average (30.9x).
PE vs Market: 600566 is good value based on its PE Ratio (12.7x) compared to the CN market (34.5x).
Price to Earnings Growth Ratio
PEG Ratio: 600566 is good value based on its PEG Ratio (0.8x)
Price to Book Ratio
PB vs Industry: 600566 is good value based on its PB Ratio (2.4x) compared to the CN Pharmaceuticals industry average (2.8x).
Future Growth
How is Hubei Jumpcan Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
15.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 600566's forecast earnings growth (15.2% per year) is above the savings rate (3.3%).
Earnings vs Market: 600566's earnings (15.2% per year) are forecast to grow slower than the CN market (23.5% per year).
High Growth Earnings: 600566's earnings are forecast to grow, but not significantly.
Revenue vs Market: 600566's revenue (12.8% per year) is forecast to grow slower than the CN market (18% per year).
High Growth Revenue: 600566's revenue (12.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 600566's Return on Equity is forecast to be low in 3 years time (16.7%).
Past Performance
How has Hubei Jumpcan Pharmaceutical performed over the past 5 years?
16.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 600566 has high quality earnings.
Growing Profit Margin: 600566's current net profit margins (21.8%) are lower than last year (23.9%).
Past Earnings Growth Analysis
Earnings Trend: 600566's earnings have grown by 16.5% per year over the past 5 years.
Accelerating Growth: 600566's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 600566 had negative earnings growth (-24.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (10.9%).
Return on Equity
High ROE: 600566's Return on Equity (17.2%) is considered low.
Financial Health
How is Hubei Jumpcan Pharmaceutical's financial position?
Financial Position Analysis
Short Term Liabilities: 600566's short term assets (CN¥6.1B) exceed its short term liabilities (CN¥1.8B).
Long Term Liabilities: 600566's short term assets (CN¥6.1B) exceed its long term liabilities (CN¥792.7M).
Debt to Equity History and Analysis
Debt Level: 600566's debt to equity ratio (8.1%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 600566's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 600566's debt is well covered by operating cash flow (298.5%).
Interest Coverage: 600566 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Hubei Jumpcan Pharmaceutical current dividend yield, its reliability and sustainability?
6.17%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 600566's dividend (6.17%) is higher than the bottom 25% of dividend payers in the CN market (0.42%).
High Dividend: 600566's dividend (6.17%) is in the top 25% of dividend payers in the CN market (1.79%)
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, 600566 has been paying a dividend for less than 10 years.
Growing Dividend: 600566's dividend payments have increased, but the company has only paid a dividend for 6 years.
Current Payout to Shareholders
Dividend Coverage: At its current payout ratio (78.6%), 600566's payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.1yrs
Average board tenure
CEO
Fei Cao (37 yo)
1.33yrs
Tenure
Mr. Fei Cao serves as General Manager of Jiangsu Jumpcan Holding Group Co., Ltd. Mr. Cao serves as Chairman of Shaanxi Dongke Pharmaceutical Co., Ltd. Mr. Cao serves as Vice Chairman of Hubei Jumpcan Pharm...
Board Members
Experienced Board: 600566's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9%.
Top Shareholders
Company Information
Hubei Jumpcan Pharmaceutical Co., Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Hubei Jumpcan Pharmaceutical Co., Ltd.
- Ticker: 600566
- Exchange: SHSE
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥17.712b
- Shares outstanding: 888.26m
- Website: https://www.jumpcan.com
Number of Employees
Location
- Hubei Jumpcan Pharmaceutical Co., Ltd.
- Baota Bay
- West Daqing Road
- Taixing
- Jiangsu Province
- 225441
- China
Listings
Biography
Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemical based Chinese traditional med...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/11 09:02 |
| End of Day Share Price | 2021/04/09 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.